Kynurenines in the CNS: Recent advances and new questions

Nature Reviews Drug Discovery

Volumn 12, Issue 1, 2013, Pages 64-82

  Vécsei, László ^a   Szalárdy, Levente ^a   Fülöp, Ferenc ^b   Toldi, József ^a,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYHIPPURIC ACID; 3 HYDROXYKYNURENINE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 4 ARYL 2 HYDROXY 4 OXOBUT 2 ENOIC ACID DERIVATIVE; 4 CHLOROKYNURENINE; 4,6 DICHLOROKYNURENINE; ANTHRANILIC ACID DERIVATIVE; AV 101; BENZENESULFONAMIDE DERIVATIVE; BICYCLICKYNURENINE DERIVATIVE; CARBAMAZEPINE; DESAMINOKYNURENINE DERIVATIVE; DIHYDROKYNURENINE DERIVATIVE; DIZOCILPINE; FCE 28833A; FELBAMATE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KYNURENIC ACID; KYNURENINE; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINYLALANINE; O AMINOBENZALDEHYDE; O METHOXYBENZOYLALANINE; PHENOBARBITAL; PHENYLCINNAMIC ACID DERIVATIVE; PHENYTOIN; QUINOLINIC ACID; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DRUG POTENCY; EPILEPSY; HUMAN; HUNTINGTON CHOREA; IMMUNOLOGICAL TOLERANCE; METABOLITE; MIGRAINE; MULTIPLE SCLEROSIS; NERVE CELL EXCITABILITY; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TRYPTOPHAN METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNE TOLERANCE; KYNURENINE; MIGRAINE DISORDERS; NEURODEGENERATIVE DISEASES; PAIN; TRYPTOPHAN;

EID: 84871925048     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3793     Document Type: Review

References (232)

1. Wolf, H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand. J. Clin. Lab. Invest. Suppl. 136, 1-186 (1974).
2. Pardridge, W. M. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem. Res. 23, 635-644 (1998). (Pubitemid 28173568)
3. Gal, E. M. & Sherman, A. D. Synthesis and metabolism of L 2011;kynurenine in rat brain. J. Neurochem. 30, 607-613 (1978). (Pubitemid 8291438)
4. Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y. & Smith, Q. R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56, 2007-2017 (1991).
5. Guillemin, G. J. Quinolinic acid, the inescapable neurotoxin. FEBS J. 279, 1356-1365 (2012). This is a comprehensive review about the possible modes of action through which quinolinic acid can contribute to degenerative CNS conditions.
6. Santamaria, A. & Rios, C. MK 2011;801, an N 2011;methyl- d2011;aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci. Lett. 159, 51-54 (1993). (Pubitemid 23283236)
7. Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,32011;dioxygenase. J. Exp. Med. 196, 459-468 (2002).
8. Szalardy, L. et al. Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr. Med. Chem. 19, 1899-1920 (2012).
9. Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,32011;dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447-457 (2002).
10. Mizdrak, J., Hains, P. G., Truscott, R. J., Jamie, J. F. & Davies, M. J. Tryptophan-derived ultraviolet filter compounds covalently bound to lens proteins are photosensitizers of oxidative damage. Free Radic. Biol. Med. 44, 1108-1119 (2008).
11. Szalardy, L. et al. Manipulating kynurenic acid levels in the brain-on the edge between neuroprotection and cognitive dysfunction. Curr. Top. Med. Chem. 12, 1797-1806 (2012).
12. Prescott, C., Weeks, A. M., Staley, K. J. & Partin, K. M. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 402, 108-112 (2006). (Pubitemid 43766458)
13. Rozsa, E., Robotka, H., Vecsei, L. & Toldi, J. The Janus-face kynurenic acid. J. Neural. Transm. 115, 1087-1091 (2008).
14. Hilmas, C. et al. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases noN 2011;α7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21, 7463-7473 (2001). (Pubitemid 32904945)
15. Marchi, M., Risso, F., Viola, C., Cavazzani, P. & Raiteri, M. Direct evidence that release-stimulating α7*nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem. 80, 1071-1078 (2002). (Pubitemid 34809959)
16. Wang, J. et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281, 22021-22028 (2006). (Pubitemid 44181906)
17. Lugo-Huitron, R. et al. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol. Teratol. 33, 538-547 (2011).
18. Winn, P., Stone, T. W., Latimer, M., Hastings, M. H. & Clark, A. J. A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N 2011;methyl-d 2011;aspartate or quisqualate, and the effects on toxicity of 22011;amino2011;52011;phosphonovaleric acid and kynurenic acid in the rat. Br. J. Pharmacol. 102, 904-908 (1991).
19. Nozaki, K. & Beal, M. F. Neuroprotective effects of l-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J. Cereb. Blood Flow Metab. 12, 400-407 (1992).
20. Sas, K. et al. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol. Dis. 32, 302-308 (2008).
21. Gigler, G. et al. Neuroprotective effect of l-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur. J. Pharmacol. 564, 116-122 (2007). (Pubitemid 46946855)
22. Robotka, H. et al. Neuroprotection achieved in the ischaemic rat cortex with l-kynurenine sulphate. Life Sci. 82, 915-919 (2008).
23. Kemp, J. A. et al. 2011;chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N 2011;methyl-d 2011;aspartate receptor complex. Proc. Natl Acad. Sci. USA 85, 6547-6550 (1988).
24. Zwilling, D. et al. Kynurenine 32011;monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874 (2011). This is the first report of a peripherally acting KMO inhibitor providing protection in transgenic models of neurodegeneration.
25. Stone, T. W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol. Sci. 21, 149-154 (2000). (Pubitemid 30190140)
26. Fulop, F. et al. Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr. Med. Chem. 16, 4828-4842 (2009).
27. Borza, I. et al. Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 17, 406-409 (2007). (Pubitemid 46073751)
28. Marosi, M. et al. A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study. J. Neural. Transm. 117, 183-188 (2010).
29. Gellert, L. et al. Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur. J. Pharmacol. 667, 182-187 (2011).
30. Zadori, D. et al. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J. Neural. Transm. 118, 865-875 (2011). This is the first report of a systemically administered kynurenic acid analogue having neuroprotective properties in a transgenic mouse model of Huntington's disease.
31. Guidetti, P., Wu, H. Q. & Schwarcz, R. In situ produced 72011;chlorokynurenate provides protection against quinolinate-and malonate-induced neurotoxicity in the rat striatum. Exp. Neurol. 163, 123-130 (2000). This is the first report showing that a halogenated kynurenic acid prodrug has a protective effect in toxin-mediated models of Huntington's disease. (Pubitemid 30314366)
32. Beal, M. F. et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171 (1986). This pioneering report shows that intrastriatal administration of quinolinic acid evokes selective neurodegeneration in a pattern that closely resembles that seen in Huntington's disease. (Pubitemid 16022019)
33. Guidetti, P., Luthi-Carter, R. E., Augood, S. J. & Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455-461 (2004). (Pubitemid 39574879)
34. Shear, D. A., Dong, J., Gundy, C. D., Haik-Creguer, K. L. & Dunbar, G. L. Comparison of intrastriatal injections of quinolinic acid and 32011;nitropropionic acid for use in animal models of Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 1217-1240 (1998). (Pubitemid 28511596)
35. Schwarcz, R., Okuno, E., White, R. J., Bird, E. D. & Whetsell, W. O. Jr. 32011;hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natl Acad. Sci. USA 85, 4079-4081 (1988).
36. Sathyasaikumar, K. V. et al. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J. Neurochem. 113, 1416-1425 (2010).
37. Beal, M. F. et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 108, 80-87 (1992).
38. Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H. & Bird, E. D. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem. 55, 1327-1339 (1990).
39. Jauch, D. et al. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J. Neurol. Sci. 130, 39-47 (1995).
40. Heyes, M. P. et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115, 1249-1273 (1992).
41. Luchowski, P., Luchowska, E., Turski, W. A. & Urbanska, E. M. 12011;methyl-42011;phenylpyridinium and 32011;nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci. Lett. 330, 49-52 (2002). (Pubitemid 35245767)
42. Csillik, A. et al. Effect of 32011;nitropropionic acid on kynurenine aminotransferase in the rat brain. Exp. Neurol. 177, 233-241 (2002). (Pubitemid 35356836)
43. Sapko, M. T. et al. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp. Neurol. 197, 31-40 (2006). (Pubitemid 41817219)
44. Zeron, M. M. et al. Increased sensitivity to N 2011;methyl-d 2011;aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860 (2002). (Pubitemid 34246352)
45. Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C. & Muchowski, P. J. A genomic screen in yeast implicates kynurenine 32011;monooxygenase as a therapeutic target for Huntington disease. Nature Genet. 37, 526-531 (2005). (Pubitemid 40617282)
46. Campesan, S. et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 21, 961-966 (2011).
47. Harris, C. A. et al. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br. J. Pharmacol. 124, 391-399 (1998). (Pubitemid 28248031)
48. Santamaria, A. et al. Systemic dL 2011;kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology 35, 23-28 (1996). (Pubitemid 26064940)
49. Hardingham, G. E., Fukunaga, Y. & Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neurosci. 5, 405-414 (2002). This paper discusses the opposing downstream effects of synaptic and extrasynaptic NMDA receptor activation, in terms of neuronal survival, and the potential roles they have in neurodegeneration. (Pubitemid 34454245)
50. Okamoto, S. et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Med. 15, 1407-1413 (2009).
51. Peres, M. F. et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24, 735-739 (2004). (Pubitemid 39209077)
52. Cananzi, A. R., D'Andrea, G., Perini, F., Zamberlan, F. & Welch, K. M. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 15, 132-135 (1995).
53. Pietrobon, D. Familial hemiplegic migraine. Neurotherapeutics 4, 274-284 (2007). (Pubitemid 46467543)
54. Anttila, V. et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nature Genet. 42, 869-873 (2010).
55. Ligthart, L. et al. Meta-analysis of genome-wide association for migraine in six population-based European cohorts. Eur. J. Hum. Genet. 19, 901-907 (2011).
56. Chasman, D. I. et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nature Genet. 43, 695-698 (2011).
57. Pardutz, A. et al. Kynurenines and headache. J. Neural. Transm. 119, 285-296 (2012).
58. Knyihar-Csillik, E. et al. Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion. Exp. Neurol. 186, 242-247 (2004). (Pubitemid 38333197)
59. Fejes, A., Pardutz, A., Toldi, J. & Vecsei, L. Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives. Curr. Neuropharmacol. 9, 376-387 (2011).
60. Vamos, E. et al. Kynurenate derivative attenuates the nitroglycerin-induced CamKIIα and CGRP expression changes. Headache 50, 834-843 (2010). This study demonstrates the efficiency of a kynurenic acid analogue in mitigating some characteristic histochemical alterations in an experimental migraine model.
61. Knyihar-Csillik, E. et al. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c2011;fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J. Neural. Transm. 114, 417-421 (2007). (Pubitemid 46474855)
62. Knyihar-Csillik, E. et al. Prevention of electrical stimulation-induced increase of c2011;fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci. Lett. 418, 122-126 (2007). (Pubitemid 46635993)
63. Knyihar-Csillik, E. et al. The kynurenate analog SZR2011;72 prevents the nitroglycerol-induced increase of c2011;fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR2011;72 and kynurenic acid. Neurosci. Res. 61, 429-432 (2008).
64. Vamos, E. et al. L 2011;kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 57, 425-429 (2009).
65. Kiss, C., Shepard, P. D., Bari, F. & Schwarcz, R. Cortical spreading depression augments kynurenate levels and reduces malonate toxicity in the rat cortex. Brain Res. 1002, 129-135 (2004). (Pubitemid 38251586)
66. Faria, L. C. & Mody, I. Protective effect of ifenprodil against spreading depression in the mouse entorhinal cortex. J. Neurophysiol. 92, 2610-2614 (2004). (Pubitemid 39298709)
67. Wang, Y. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nature Med. 16, 279-285 (2010).
68. Sas, K., Csete, K., Vecsei, L. & Papp, J. G. Effect of systemic administration of L 2011;kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits. J. Cardiovasc. Pharmacol. 42, 403-409 (2003). (Pubitemid 37071697)
69. Akerman, S., Williamson, D. J., Kaube, H. & Goadsby, P. J. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br. J. Pharmacol. 137, 62-68 (2002). (Pubitemid 34983464)
70. Fujigaki, S. et al. L 2011;tryptophan-L 2011;kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in γ interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine2011;2,32011;dioxygenase. Infect. Immun. 70, 779-786 (2002). (Pubitemid 34083840)
71. Prandota, J. Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches. Am. J. Ther. 14, 63-105 (2007). (Pubitemid 46296751)
72. Koseoglu, E., Yazar, S. & Koc, I. Is Toxoplasma gondii a causal agent in migraine? Am. J. Med. Sci. 338, 120-122 (2009).
73. Mandi, Y. & Vecsei, L. The kynurenine system and immunoregulation. J. Neural. Transm. 119, 197-209 (2011).
74. Kwidzinski, E. & Bechmann, I. IDO expression in the brain: a double-edged sword. J. Mol. Med. 85, 1351-1359 (2007). (Pubitemid 350234090)
75. Bozza, S. et al. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J. Immunol. 174, 2910-2918 (2005). (Pubitemid 40279709)
76. Potula, R. et al. Inhibition of indoleamine 2,32011;dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV2011;1 encephalitis. Blood 106, 2382-2390 (2005). (Pubitemid 41510811)
77. Hwu, P. et al. Indoleamine 2,32011;dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164, 3596-3599 (2000). (Pubitemid 30169812)
78. Mellor, A. L. et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA42011;mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16, 1391-1401 (2004). (Pubitemid 39341552)
79. Baban, B. et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 17, 909-919 (2005). (Pubitemid 41417958)
80. Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999). (Pubitemid 29227522)
81. Lee, G. K. et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107, 452-460 (2002). (Pubitemid 36693650)
82. Fallarino, F. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069-1077 (2002).
83. Bauer, T. M. et al. Studying the immunosuppressive role of indoleamine 2,32011;dioxygenase: tryptophan metabolites suppress rat allogeneic T 2011;cell responses in vitro and in vivo. Transpl. Int. 18, 95-100 (2005). (Pubitemid 41742952)
84. Della Chiesa, M. et al. The tryptophan catabolite L 2011;kynurenine inhibits the surface expression of NKp46-and NKG2d 2011;activating receptors and regulates NK 2011;cell function. Blood 108, 4118-4125 (2006). (Pubitemid 44913283)
85. Fallarino, F. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752-6761 (2006). (Pubitemid 43787857)
86. Pallotta, M. T. et al. Indoleamine 2,32011;dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nature Immunol. 12, 870-878 (2011).
87. Belladonna, M. L. et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 177, 130-137 (2006). (Pubitemid 43939124)
88. Yan, Y. et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 185, 5953-5961 (2010).
89. Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190-3198 (2010).
90. Forouzandeh, F., Jalili, R. B., Germain, M., Duronio, V. & Ghahary, A. Differential immunosuppressive effect of indoleamine 2,32011;dioxygenase (IDO) on primary human CD4+ and CD8+ T cells. Mol. Cell. Biochem. 309, 1-7 (2008).
91. Kanai, M., Hiroshi, F. & Toshikazu, N. Implication of tryptophan 2,32011;dioxygenase and its novel variants in the hippocampus and cerebellum during the developing and adult brain. Int. J. Tryptophan Res. 3, 141-149 (2010).
92. Guillemin, G. J. et al. Characterization of the kynurenine pathway in human neurons. J. Neurosci. 27, 12884-12892 (2007). (Pubitemid 350161746)
93. Ball, H. J. et al. Characterization of an indoleamine 2,32011;dioxygenase-like protein found in humans and mice. Gene 396, 203-213 (2007). (Pubitemid 46818792)
94. Metz, R. et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,32011;dioxygenase inhibitory compound d-12011;methyl-tryptophan. Cancer Res. 67, 7082-7087 (2007). (Pubitemid 47206533)
95. Lob, S. et al. Levo-but not dextro-12011;methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111, 2152-2154 (2008). (Pubitemid 351451527)
96. Lob, S. et al. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-12011;methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58, 153-157 (2009).
97. Aranami, T. & Yamamura, T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int. 57, 115-120 (2008). (Pubitemid 351897665)
98. Sakurai, K., Zou, J. P., Tschetter, J. R., Ward, J. M. & Shearer, G. M. Effect of indoleamine 2,32011;dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129, 186-196 (2002). (Pubitemid 34874924)
99. Kwidzinski, E. et al. Indolamine 2,32011;dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 19, 1347-1349 (2005). (Pubitemid 41113745)
100. Platten, M. et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310, 850-855 (2005). (Pubitemid 41567343)
101. Mai, J., Wang, H. & Yang, X. F. Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front. Biosci. 15, 986-1006 (2010).
102. Xiao, B. G. et al. Therapeutic potential of IFN-γ-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int. Immunol. 16, 13-22 (2004).
103. Platten, M., Ho, P. P. & Steinman, L. Anti-inflammatory strategies for the treatment of multiple sclerosis-tryptophan catabolites may hold the key. Inflammation 3, 401-408 (2006). (Pubitemid 44774491)
104. Polman, C. et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64, 987-991 (2005). (Pubitemid 40388448)
105. Comi, G. et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371, 2085-2092 (2008). (Pubitemid 351842581)
106. Comi, G. et al. Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment. Neurology 78, Abstract P04.132 (2012).
107. O'Connor, P. W. et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894-900 (2006). (Pubitemid 43739766)
108. O'Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293-1303 (2011).
109. Confavreux, C. et al. Long-term follow2011;up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult. Scler. 18, 1278-1289 (2012).
110. Flanagan, E. M., Erickson, J. B., Viveros, O. H., Chang, S. Y. & Reinhard, J. F. Jr. Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis. J. Neurochem. 64, 1192-1196 (1995).
111. Chiarugi, A., Cozzi, A., Ballerini, C., Massacesi, L. & Moroni, F. Kynurenine 32011;mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 102, 687-695 (2001). (Pubitemid 32171887)
112. Alberati-Giani, D., Ricciardi-Castagnoli, P., Kohler, C. & Cesura, A. M. Regulation of the kynurenine metabolic pathway by interferon-γ in murine cloned macrophages and microglial cells. J. Neurochem. 66, 996-1004 (1996). (Pubitemid 26065895)
113. Xiao, B. G., Liu, X. & Link, H. Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2,32011;dioxygenase axis. Steroids 69, 653-659 (2004). (Pubitemid 39297704)
114. Lim, C. K., Brew, B. J., Sundaram, G. & Guillemin, G. J. Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int. J. Tryptophan Res. 3, 157-167 (2010).
115. Monaco, F., Fumero, S., Mondino, A. & Mutani, R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. J. Neurol. Neurosurg. Psychiatry 42, 640-641 (1979). (Pubitemid 9187862)
116. Ott, M., Demisch, L., Engelhardt, W. & Fischer, P. A. InterleukiN 2011; 2, soluble interleukin-22011;receptor, neopterin, L 2011;tryptophan and β22011;microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J. Neurol. 241, 108-114 (1993). (Pubitemid 23362659)
117. Amirkhani, A. et al. Interferon-β affects the tryptophan metabolism in multiple sclerosis patients. Eur. J. Neurol. 12, 625-631 (2005). This paper shows that administration of IFNβ to patients with multiple sclerosis is associated with a subsequent increase in IDO activity in the bloodstream. (Pubitemid 41117289)
118. Rejdak, K. et al. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J. Neural. Transm. 114, 1011-1015 (2007). (Pubitemid 47106447)
119. Rejdak, K. et al. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett. 331, 63-65 (2002). (Pubitemid 35279383)
120. Hartai, Z. et al. Kynurenine metabolism in multiple sclerosis. Acta Neurol. Scand. 112, 93-96 (2005). (Pubitemid 41003368)
121. Baran, H. et al. Lowered kynurenine aminotransferase activities in CNS of MS patients. Program No. 481.12 In: Society for Neuroscience 30th Annual Meeting (New Orleans, 2000).
122. Guillemin, G. J. et al. IFN 2011;β1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J. Interferon Cytokine Res. 21, 1097-1101 (2001). (Pubitemid 34114289)
123. Sardar, A. M. & Reynolds, G. P. Frontal cortex indoleamine2011;2, 32011;dioxygenase activity is increased in HIV2011;12011;associated dementia. Neurosci. Lett. 187, 9-12 (1995).
124. Cammer, W. Oligodendrocyte killing by quinolinic acid in vitro. Brain Res. 896, 157-160 (2001). (Pubitemid 32244159)
125. Tiszlavicz, Z. et al. Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP 1 2011;3 secretion by neutrophils. Naunyn Schmiedebergs Arch. Pharmacol. 383, 447-455 (2011).
126. Varga, G. et al. N 2011;methyl-d 2011;aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. Neurogastroenterol. Motil. 22, 217-225 (2010).
127. Kaszaki, J. et al. Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterol. Motil. 20, 53-62 (2008). (Pubitemid 350277448)
128. Mazzoni, O. et al. Synthesis and pharmacological evaluation of some 42011;oxo-quinoline-22011;carboxylic acid derivatives as anti-inflammatory and analgesic agents. Arch. Pharm. 343, 561-569 (2010).
129. Fallarini, S., Magliulo, L., Paoletti, T., de Lalla, C. & Lombardi, G. Expression of functional GPR35 in human iNKT cells. Biochem. Biophys. Res. Commun. 398, 420-425 (2010).
130. Cantorna, M. T., Zhao, J. & Yang, L. Vitamin D, invariant natural killer T 2011;cells and experimental autoimmune disease. Proc. Nutr. Soc. 71, 62-66 (2012).
131. Gigli, G., Caielli, S., Cutuli, D. & Falcone, M. Innate immunity modulates autoimmunity: type 1 interferon-β treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 122, 409-417 (2007). (Pubitemid 47556478)
132. Oki, S. & Miyake, S. Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases. Allergol. Int. 56, 7-14 (2007). (Pubitemid 46449657)
133. Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197-203 (2011).
134. Han, Q. Li, J. & Li, J. pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I. Eur. J. Biochem. 271, 4804-4814 (2004). (Pubitemid 40065583)
135. Schwarcz, R., Bruno, J. P., Muchowski, P. J. & Wu, H. Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nature Rev. Neurosci. 13, 465-477 (2012).
136. Alkondon, M. et al. Age dependency of inhibition of α7 nicotinic receptors and tonically active N 2011;methyl-d 2011;aspartate receptors by endogenously produced kynurenic acid in the brain. J. Pharmacol. Exp. Ther. 337, 572-582 (2011).
137. Luchowska, E. et al. Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus. Pol. J. Pharmacol. 55, 443-447 (2003). (Pubitemid 36975212)
138. Darlington, L. G. et al. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur. J. Neurosci. 26, 2211-2221 (2007). (Pubitemid 47620487)
139. Gold, A. B. et al. The relationship between indoleamine 2,32011;dioxygenase activity and post-stroke cognitive impairment. J. Neuroinflamm. 8, 17 (2011).
140. Saito, K., Nowak, T. S. Jr., Markey, S. P. & Heyes, M. P. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J. Neurochem. 60, 180-192 (1993). (Pubitemid 23006716)
141. Cozzi, A., Carpenedo, R. & Moroni, F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m2011;nitrobenzoyl)- alanine (mNBA) and 3,42011;dimethoxy-[-N-4-(nitrophenyl)thiazoL 2011;2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab. 19, 771-777 (1999). (Pubitemid 30159803)
142. Baran, H., Jellinger, K. & Deecke, L. Kynurenine metabolism in Alzheimer's disease. J. Neural. Transm. 106, 165-181 (1999). (Pubitemid 29137514)
143. Hartai, Z. et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem. Int. 50, 308-313 (2007). (Pubitemid 46097159)
144. Widner, B. et al. Degradation of tryptophan in neurodegenerative disorders. Adv. Exp. Med. Biol. 467, 133-138 (1999). (Pubitemid 32202153)
145. Widner, B. et al. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural. Transm. 107, 343-353 (2000). (Pubitemid 30162696)
146. Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O. & Cullen, K. M. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 31, 395-404 (2005). (Pubitemid 41059860)
147. Guillemin, G. J., Smythe, G. A., Veas, L. A., Takikawa, O. & Brew, B. J. Aβ1-42 induces production of quinolinic acid by human macrophages and microglia. NeuroReport 14, 2311-2315 (2003).
148. Rahman, A. et al. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS ONE 4, e6344 (2009).
149. Carrillo-Mora, P., Mendez-Cuesta, L. A., Perez2011;De La Cruz, V., Fortoul-van Der Goes, T. I. & Santamaria, A. Protective effect of systemic L 2011;kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus. Behav. Brain Res. 210, 240-250 (2010).
150. Wu, H. Q., Lee, S. C. & Schwarcz, R. Systemic administration of 42011;chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur. J. Pharmacol. 390, 267-274 (2000). (Pubitemid 30119941)
151. Ogawa, T. et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42, 1702-1706 (1992).
152. Widner, B., Leblhuber, F. & Fuchs, D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J. Neural. Transm. 109, 181-189 (2002). (Pubitemid 34185664)
153. Knyihar-Csillik, E. et al. Decreased expression of kynurenine aminotransferase2011;I (KAT 2011;I) in the substantia nigra of mice after 12011;methyl-42011;phenyL 2011; 1,2,3,62011;tetrahydropyridine (MPTP) treatment. Neuroscience 126, 899-914 (2004). (Pubitemid 38780895)
154. Lee do, Y. et al. Kynurenic acid attenuates MPP+-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. Eur. J. Cell Biol. 87, 389-397 (2008).
155. Miranda, A. F., Boegman, R. J., Beninger, R. J. & Jhamandas, K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78, 967-975 (1997). (Pubitemid 27223703)
156. Silva-Adaya, D. et al. Protective effect of L 2011;kynurenine and probenecid on 62011;hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol. Teratol. 33, 303-312 (2011).
157. Merino, M., Vizuete, M. L., Cano, J. & Machado, A. The non-NMDA glutamate receptor antagonists 62011;cyano2011;72011;nitroquinoxaline2011;2, 32011;dione and 2,32011;dihydroxy-62011;nitro2011;72011;sulfamoylbenzo(f) quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. J. Neurochem. 73, 750-757 (1999). (Pubitemid 29339850)
158. Pearson, S. J. & Reynolds, G. P. Increased brain concentrations of a neurotoxin, 32011;hydroxykynurenine, in Huntington's disease. Neurosci. Lett. 144, 199-201 (1992).
159. Guidetti, P., Reddy, P. H., Tagle, D. A. & Schwarcz, R. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci. Lett. 283, 233-235 (2000). (Pubitemid 30168976)
160. Stoy, N. et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 93, 611-623 (2005). (Pubitemid 40617621)
161. Guidetti, P. et al. Elevated brain 32011;hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 23, 190-197 (2006). (Pubitemid 43922462)
162. Chen, Y. et al. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox. Res. 18, 132-142 (2010).
163. Ilzecka, J., Kocki, T., Stelmasiak, Z. & Turski, W. A. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol. Scand. 107, 412-418 (2003). (Pubitemid 36683472)
164. Chen, Y., Brew, B. J. & Guillemin, G. J. Characterization of the kynurenine pathway in NSC2011;34 cell line: implications for amyotrophic lateral sclerosis. J. Neurochem. 118, 816-825 (2011).
165. Yamamoto, H., Shindo, I., Egawa, B. & Horiguchi, K. Kynurenic acid is decreased in cerebrospinal fluid of patients with infantile spasms. Pediatr. Neurol. 10, 9-12 (1994). (Pubitemid 24096714)
166. Yamamoto, H. Studies on CSF tryptophan metabolism in infantile spasms. Pediatr. Neurol. 7, 411-414 (1991).
167. Langlais, P. J., Wardlow, M. L. & Yamamoto, H. Changes in CSF neurotransmitters in infantile spasms. Pediatr. Neurol. 7, 440-445 (1991).
168. Yamamoto, H., Murakami, H., Horiguchi, K. & Egawa, B. Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children. Brain Dev. 17, 327-329 (1995).
169. Heyes, M. P., Saito, K., Devinsky, O. & Nadi, N. S. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures. Epilepsia 35, 251-257 (1994). (Pubitemid 24138806)
170. Rozsa, E. et al. The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of L 2011;kynurenine to kynurenic acid: an in vitro study. Brain Res. Bull. 76, 474-479 (2008).
171. Nemeth, H. et al. Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology 47, 916-925 (2004). (Pubitemid 39440985)
172. Robotka, H., Nemeth, H., Somlai, C., Vecsei, L. & Toldi, J. Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur. J. Pharmacol. 513, 75-80 (2005). (Pubitemid 40692248)
173. Battaglia, G. et al. Systemically administered d 2011;glucose conjugates of 72011;chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res. 860, 149-156 (2000). (Pubitemid 30155848)
174. Demeter, I. et al. A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study: special issue related to kynurenine. J. Neural. Transm. 119, 151-154 (2012).
175. Kocki, T., Wielosz, M., Turski, W. A. & Urbanska, E. M. Enhancement of brain kynurenic acid production by anticonvulsants-novel mechanism of antiepileptic activity? Eur. J. Pharmacol. 541, 147-151 (2006). (Pubitemid 43903484)
176. Qu, X. X. et al. Role of the spinal cord NR2B2011;containing NMDA receptors in the development of neuropathic pain. Exp. Neurol. 215, 298-307 (2009).
177. Christoph, T., Reissmuller, E., Schiene, K., Englberger, W. & Chizh, B. A. Antiallodynic effects of NMDA glycineB antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res. 1048, 218-227 (2005). (Pubitemid 40803505)
178. Heyliger, S. O., Goodman, C. B., Ngong, J. M. & Soliman, K. F. The analgesic effects of tryptophan and its metabolites in the rat. Pharmacol. Res. 38, 243-250 (1998). (Pubitemid 28466743)
179. Richter, R. C. & Behbehani, M. M. Evidence for glutamic acid as a possible neurotransmitter between the mesencephalic nucleus cuneiformis and the medullary nucleus raphe magnus in the lightly anesthetized rat. Brain Res. 544, 279-286 (1991).
180. Beitz, A. J. Relationship of glutamate and aspartate to the periaqueductal gray-raphe magnus projection: analysis using immunocytochemistry and microdialysis. J. Histochem. Cytochem. 38, 1755-1765 (1990). (Pubitemid 20382391)
181. Olpe, H. R., Steinmann, M. W., Brugger, F. & Pozza, M. F. Excitatory amino acid receptors in rat locus coeruleus. An extracellular in vitro study. Naunyn Schmiedebergs Arch. Pharmacol. 339, 312-314 (1989).
182. Kalen, P., Strecker, R. E., Rosengren, E. & Bjorklund, A. Regulation of striatal serotonin release by the lateral habenula-dorsal raphe pathway in the rat as demonstrated by in vivo microdialysis: role of excitatory amino acids and GABA. Brain Res. 492, 187-202 (1989). (Pubitemid 19184550)
183. Reinhard, J. F. Jr. Pharmacological manipulation of brain kynurenine metabolism. Ann. NY Acad. Sci.1035, 335-349 (2004). (Pubitemid 40362342)
184. Speciale, C. et al. (R,S)-3,42011;dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur. J. Pharmacol. 315, 263-267 (1996). (Pubitemid 26414271)
185. Rover, S., Cesura, A. M., Huguenin, P., Kettler, R. & Szente, A. Synthesis and biochemical evaluation of N-(42011;phenylthiazol-22011;yl) benzenesulfonamides as high-affinity inhibitors of kynurenine 32011;hydroxylase. J. Med. Chem. 40, 4378-4385 (1997). (Pubitemid 28042317)
186. Pellicciari, R. et al. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m2011;nitrobenzoyl) alanine, a potent inhibitor of kynurenine- 32011;hydroxylase. J. Med. Chem. 37, 647-655 (1994). (Pubitemid 24102185)
187. Natalini, B. et al. Synthesis and activity of enantiopure (S) (m2011;nitrobenzoyl) alanine, potent kynurenine-32011;hydroxylase inhibitor. Bioorg. Med. Chem. Lett. 5, 1451-1454 (1995).
188. Carpenedo, R. et al. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61, 237-243 (1994).
189. Pellicciari, R. et al. Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine- 32011;hydroxylase. Adv. Exp. Med. Biol. 527, 621-628 (2003). (Pubitemid 38197691)
190. Walsh, J. L., Todd, W. P., Carpenter, B. K. & Schwarcz, R. 42011;halo2011;32011;hydroxyanthranilic acids: potent competitive inhibitors of 32011;hydroxy-anthranilic acid oxygenase in vitro. Biochem. Pharmacol. 42, 985-990 (1991).
191. Linderberg, M. et al. Synthesis and QSAR of substituted 32011;hydroxyanthranilic acid derivatives as inhibitors of 32011; hydroxyanthranilic acid dioxygenase (32011;HAO). Eur. J. Med. Chem. 34, 729-744 (1999). (Pubitemid 29491558)
192. Walsh, H. A., Leslie, P. L., O'Shea, K. C. & Botting, N. P. 22011;amino2011;4-[3?2011;hydroxyphenyl]-42011;hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg. Med. Chem. Lett. 12, 361-363 (2002). (Pubitemid 34113903)
193. Walsh, H. A., O'Shea, K. C. & Botting, N. P. Comparative inhibition by substrate analogues 32011;methoxy-and 32011;hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 4, 13 (2003).
194. Fitzgerald, D. H., Muirhead, K. M. & Botting, N. P. A comparative study on the inhibition of human and bacterial kynureninase by novel bicyclic kynurenine analogues. Bioorg. Med. Chem. 9, 983-989 (2001). (Pubitemid 32448118)
195. Lima, S., Kumar, S., Gawandi, V., Momany, C. & Phillips, R. S. Crystal structure of the Homo sapiens kynureninase-32011;hydroxyhippuric acid inhibitor complex: insights into the molecular basis of kynureninase substrate specificity. J. Med. Chem. 52, 389-396 (2009).
196. Tanizawa, K. & Soda, K. The mechanism of kynurenine hydrolysis catalyzed by kynureninase. J. Biochem. 86, 1199-1209 (1979).
197. Alberati-Giani, D. et al. Isolation and expression of a cDNA clone encoding human kynureninase. Eur. J. Biochem. 239, 460-468 (1996). (Pubitemid 26246554)
198. Chiarugi, A. & Moroni, F. Effects of mitochondria and o2011;methoxybenzoylalanine on 32011;hydroxyanthranilic acid dioxygenase activity and quinolinic acid synthesis. J. Neurochem. 72, 1125-1132 (1999). (Pubitemid 29085027)
199. Dua, R. K., Taylor, E. W. & Phillips, R. S. S2011;aryL 2011;L 2011;cysteine S,S2011;dioxides: design, synthesis, and evaluation of a new class of inhibitors of kynureninase. J. Am. Chem. Soc. 115, 1264-1270 (1993). (Pubitemid 23122470)
200. Heiss, C., Anderson, J. & Phillips, R. S. Differential effects of bromination on substrates and inhibitors of kynureninase from Pseudomonas fluorescens. Org. Biomol. Chem. 1, 288-295 (2003).
201. Drysdale, M. J. & Reinhard, J. F. S2011;aryl cysteine S,S2011;dioxides as inhibitors of mammalian kynureninase. Bioorg. Med. Chem. Lett. 8, 133-138 (1998). (Pubitemid 28037170)
202. Smith, J. R. et al. Novel indoleamine 2,32011;dioxygenase2011;1 inhibitors from a multistep in silico screen. Bioorg. Med. Chem. 20, 1354-1363 (2012).
203. Yue, E. W. et al. Discovery of potent competitive inhibitors of indoleamine 2,32011;dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J. Med. Chem. 52, 7364-7367 (2009).
204. Meininger, D. et al. Purification and kinetic characterization of human indoleamine 2,32011;dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim. Biophys. Acta 1814, 1947-1954 (2011).
205. Rohrig, U. F. et al. Rational design of 42011;aryL 2011;1,2, 32011;triazoles for indoleamine 2,32011;dioxygenase 1 inhibition. J. Med. Chem. 55, 5270-5290 (2012).
206. Yu, C. J., Zheng, M. F., Kuang, C. X., Huang, W. D. & Yang, Q. Oren-gedoku2011;to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2,32011;dioxygenase activity in vitro. J. Alzheimers Dis. 22, 257-266 (2010).
207. Matsuno, K. et al. S2011;benzylisothiourea derivatives as small-molecule inhibitors of indoleamine2011; 2,32011;dioxygenase. Bioorg. Med. Chem. Lett. 20, 5126-5129 (2010).
208. Eguchi, N., Watanabe, Y., Kawanishi, K., Hashimoto, Y. & Hayaishi, O. Inhibition of indoleamine 2,32011;dioxygenase and tryptophan 2,32011;dioxygenase by β-carboline and indole derivatives. Arch. Biochem. Biophys. 232, 602-609 (1984).
209. Grant, R. & Kapoor, V. Inhibition of indoleamine 2,32011;dioxygenase activity in IFN-γ stimulated astroglioma cells decreases intracellular NAD levels. Biochem. Pharmacol. 66, 1033-1036 (2003). (Pubitemid 37083599)
210. Peterson, A. et al. Evaluation of substituted β2011;carbolines as noncompetitive indoleamine 2,32011;dioxygenase inhibitors. Med. Chem. Res. 3, 473-482 (1993).
211. Gaspari, P. et al. Structure-activity study of brassinin derivatives as indoleamine 2,32011;dioxygenase inhibitors. J. Med. Chem. 49, 684-692 (2006). (Pubitemid 43157498)
212. Banerjee, T. et al. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,32011;dioxygenase. Oncogene 27, 2851-2857 (2008). (Pubitemid 351620442)
213. Saito, K. et al. 42011;chloro-32011;hydroxyanthranilate, 62011;chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-γ-stimulated monocytes (THP2011;1 cells). Biochem. J. 291, 11-14 (1993). (Pubitemid 23107741)
214. Cao, D. et al. Diindolylmethane inhibits indoleamine 2,32011;dioxygenase activity in breast cancer cells. Proc. Amer. Assoc. Cancer Res. 46, Abstract 2461 (2005).
215. Pereira, A., Vottero, E., Roberge, M., Mauk, A. G. & Andersen, R. J. Indoleamine 2,32011;dioxygenase inhibitors from the northeastern pacific marine hydroid Garveia annulata. J. Nature Prod. 69, 1496-1499 (2006). (Pubitemid 44899767)
216. Dolusic, E. et al. IndoL 2011;22011;yl ethanones as novel indoleamine 2,32011;dioxygenase (IDO) inhibitors. Bioorg. Med. Chem. 19, 1550-1561 (2011).
217. Rohrig, U. F. et al. Rational design of indoleamine 2,32011;dioxygenase inhibitors. J. Med. Chem. 53, 1172-1189 (2010).
218. Hou, D. Y. et al. Inhibition of indoleamine 2,32011;dioxygenase in dendritic cells by stereoisomers of 12011;methyl-tryptophan correlates with antitumor responses. Cancer Res. 67, 792-801 (2007).
219. Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Inhibition of indoleamine 2,32011;dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Med. 11, 312-319 (2005). (Pubitemid 40460560)
220. Vottero, E. et al. Inhibitors of human indoleamine 2,32011;dioxygenase identified with a target-based screen in yeast. Biotechnol. J. 1, 282-288 (2006).
221. Kumar, S. et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,32011;dioxygenase. J. Med. Chem. 51, 4968-4977 (2008).
222. Carr, G. et al. Plectosphaeroic acids A, B, and C, indoleamine 2,32011;dioxygenase inhibitors produced in culture by a marine isolate of the fungus Plectosphaerella cucumerina. Org. Lett. 11, 2996-2999 (2009).
223. Terentis, A. C. et al. The selenazal drug ebselen potently inhibits indoleamine 2,32011;dioxygenase by targeting enzyme cysteine residues. Biochemistry 49, 591-600 (2010).
224. Carr, G., Chung, M. K., Mauk, A. G. & Andersen, R. J. Synthesis of indoleamine 2,32011;dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J. Med. Chem. 51, 2634-2637 (2008). (Pubitemid 351620784)
225. Volgraf, M. et al. Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nature Chem. Biol. 4, 535-537 (2008).
226. Koblish, H. K. et al. Hydroxyamidine inhibitors of indoleamine2011;2, 32011;dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol. Cancer Ther. 9, 489-498 (2010).
227. Liu, X. et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115, 3520-3530 (2010).
228. Kumar, S. et al. Indoleamine 2,32011;dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J. Med. Chem. 51, 1706-1718 (2008). (Pubitemid 351438852)
229. John, S., Thangapandian, S., Sakkiah, S. & Lee, K. W. Identification of potent virtual leads to design novel indoleamine 2,32011;dioxygenase inhibitors: pharmacophore modeling and molecular docking studies. Eur. J. Med. Chem. 45, 4004-4012 (2010).
230. Comi, G. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366, 1000-1009 (2012).
231. Freedman, M. S. et al. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology 78, 1877-1885 (2012).
232. Miller, A. E. et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult. Scler. 18, 1625-1632 (2012).